Clinical utility of sample preheat treatment in a modified Nijmegen‐Bethesda assay (mNBA) for inhibitor monitoring in congenital and acquired haemophilia A: A single‐centre four‐year experience

Haemophilia ◽  
2020 ◽  
Vol 26 (6) ◽  
Author(s):  
Tejas Gandhi ◽  
Pura Lawler ◽  
Eleanor Foxton ◽  
Pratima Chowdary ◽  
Anne Riddell
Keyword(s):  
Clinical Utility ◽  
Haemophilia A ◽  
Single Centre ◽  
Acquired Haemophilia ◽  
Preheat Treatment

scholarly journals Single centre experience on Acquired Haemophilia A patients: Diagnosis, clinical management and analysis of factors predictive of response and outcome

Haemophilia ◽  
2021 ◽  
Author(s):  
Marika Porrazzo ◽  
Erminia Baldacci ◽  
Antonietta Ferretti ◽  
Maria Lucia De Luca ◽  
Francesco Barone ◽  
...  
Keyword(s):  
Clinical Management ◽  
Haemophilia A ◽  
Single Centre ◽  
Acquired Haemophilia ◽  
Single Centre Experience

Acquired haemophilia A treated with recombinant porcine factor VIII: a single centre UK experience

2020 ◽  
Vol 189 (4) ◽  
Author(s):  
Dalia Khan ◽  
Sayma Raza‐Burton ◽  
Peter Baker ◽  
Sarah Harper ◽  
James Beavis ◽  
...  
Keyword(s):  
Factor Viii ◽  
Haemophilia A ◽  
Single Centre ◽  
Acquired Haemophilia

Postpartum acquired haemophilia: a single centre experience with rituximab

Haemophilia ◽  
2009 ◽  
Vol 15 (5) ◽  
pp. 1166-1168 ◽  
Author(s):  
L. DEDEKEN ◽  
J. ST-LOUIS ◽  
C. DEMERS ◽  
C. MEILLEUR ◽  
G. E. RIVARD
Keyword(s):  
Haemophilia A ◽  
Single Centre ◽  
Acquired Haemophilia ◽  
Single Centre Experience

Rituximab as first-line therapy for acquired haemophilia A: a single-centre 10-year experience

Haemophilia ◽  
2016 ◽  
Vol 22 (4) ◽  
pp. e338-e341 ◽  
Author(s):  
B. Rossi ◽  
P. Blanche ◽  
V. Roussel-Robert ◽  
A. Berezné ◽  
S. Combe ◽  
...  
Keyword(s):  
Haemophilia A ◽  
First Line ◽  
Single Centre ◽  
Acquired Haemophilia ◽  
First Line Therapy ◽  
Line Therapy

Acquired haemophilia A and late development of secondary autoimmune disorders, evidences from a single-centre observational study

2020 ◽  
Vol 31 (7) ◽  
pp. 495-499
Author(s):  
Cristina Dainese ◽  
Jacopo A. Giacchello ◽  
Federica Valeri ◽  
Enrico Dosio ◽  
Alessandra Valpreda ◽  
...  
Keyword(s):  
Observational Study ◽  
Autoimmune Disorders ◽  
Haemophilia A ◽  
Late Development ◽  
Single Centre ◽  
Acquired Haemophilia

Younger age at presentation of acquired haemophilia A in Asian countries: a single-centre study and systematic review

Haemophilia ◽  
2014 ◽  
Vol 20 (3) ◽  
pp. e205-e210 ◽  
Author(s):  
C. Chai-Adisaksopha ◽  
E. Rattarittamrong ◽  
L. Norasetthada ◽  
A. Tantiworawit ◽  
W. Nawarawong
Keyword(s):  
Systematic Review ◽  
Haemophilia A ◽  
Asian Countries ◽  
Single Centre ◽  
Centre Study ◽  
Acquired Haemophilia ◽  
Younger Age ◽  
Single Centre Study

Clinical features and outcome of acquired haemophilia A

2010 ◽  
Vol 30 (03) ◽  
pp. 156-161 ◽  
Author(s):  
R. Gheisari ◽  
B. Bomke ◽  
T. Hoffmann ◽  
R. E. Scharf
Keyword(s):  
Respiratory Diseases ◽  
Care Center ◽  
Treatment Algorithm ◽  
Early Death ◽  
Underlying Disease ◽  
Pulmonary Sarcoidosis ◽  
Relative Increase ◽  
Laboratory Evaluation ◽  
Haemophilia A ◽  
Acquired Haemophilia

SummaryWe have performed a monocenter study on 29 consecutive patients with acquired haemophilia A who were referred for diagnosis and treatment to the Düsseldorf Haemophilia Comprehensive Care Center between March 2001 and February 2010. Patients, methods: 18 men (age: 44–86 years) and 11 women (age: 20–83 years). For laboratory evaluation, a standardized staged protocol of aPTT, FVIII : C activity and concentration, mixing studies with patient and normal plasma, and quantification of inhibitor titers (Bethesda assay) was used. Diagnostic work-up included elaborate examinations for any underlying disease. Results: In 18 (62%) of the 29 patients with acquired haemophilia A, an underlying disorder was identified, including 9 patients with respiratory diseases (31%), 7 patients with autoimmune disorders (24%), one with malignancy, and one with postpartum state, while in 11 patients (38%) acquired haemophilia A remained idiopathic. Haemotherapy of bleeding, suppression or elimination of the inhibitor, and induction of immunotolerance to endogenous FVIII:C were performed according to a treatment algorithm. Predefined clinical endpoints were control of bleeding, eradication of the inhibitor, complete or partial remission (CR, PR), relapse, or early death (≤30 days). Of the 29 patients in total, 22 individuals achieved CR (76%), three had PR, one relapsed, and three died within 30 days (one of acute myocardial infarction while on anti-haemorrhagic treatment, one of sepsis while on immunosuppression due to active acquired haemophilia A, one of lung bleeding in association with pre-existing pulmonary sarcoidosis). Conclusion: This monocenter study demonstrates that control of life-threatening bleeding, eradication of the inhibitor, and induction of tolerance to endogenous FVIII have significantly improved the clinical outcome of acquired haemophilia A. Our data also suggest a shift in underlying disorders associated with acquired haemophilia A, whereby, in comparison to published studies, a relative increase in the proportion of patients with respiratory diseases is present.

Sign in / Sign up

Export Citation Format

Share Document